The estimated Net Worth of John P Sharp is at least $1.15 Milione dollars as of 3 November 2021. Mr. Sharp owns over 7,500 units of PhaseBio Pharmaceuticals stock worth over $4,046 and over the last 18 years he sold PHAS stock worth over $395,999. In addition, he makes $747,863 as Chief Financial Officer at PhaseBio Pharmaceuticals.
John has made over 9 trades of the PhaseBio Pharmaceuticals stock since 2013, according to the Form 4 filled with the SEC. Most recently he exercised 7,500 units of PHAS stock worth $12,600 on 3 November 2021.
The largest trade he's ever made was exercising 86,953 units of PhaseBio Pharmaceuticals stock on 12 February 2014 worth over $1,527,764. On average, John trades about 5,362 units every 111 days since 2007. As of 3 November 2021 he still owns at least 57,724 units of PhaseBio Pharmaceuticals stock.
You can see the complete history of Mr. Sharp stock trades at the bottom of the page.
John P. Sharp CPA serves as Chief Financial Officer of the Company. Prior to joining our company, Mr. Sharp served as chief financial officer of HUYA Bioscience International, LLC from March 2014 to December 2015. Mr. Sharp received a B.S. in business administration from San Diego State University and is a certified public accountant.
As the Chief Financial Officer of PhaseBio Pharmaceuticals, the total compensation of John Sharp at PhaseBio Pharmaceuticals is $747,863. There are 3 executives at PhaseBio Pharmaceuticals getting paid more, with Jonathan Mow having the highest compensation of $1,203,070.
John Sharp is 55, he's been the Chief Financial Officer of PhaseBio Pharmaceuticals since 2016. There are 7 older and 9 younger executives at PhaseBio Pharmaceuticals. The oldest executive at PhaseBio Pharmaceuticals, Inc. is Nancy Hutson, 70, who is the Independent Director.
John's mailing address filed with the SEC is C/O PHASEBIO PHARMACEUTICALS, INC., 1 GREAT VALLEY PARKWAY, SUITE 30, MALVERN, PA, 19355.
Over the last 6 years, insiders at PhaseBio Pharmaceuticals have traded over $361,083 worth of PhaseBio Pharmaceuticals stock and bought 24,000 units worth $81,960 . The most active insiders traders include Clay Thorp, Enterprise Associates 13 Lp... e Nancy J Hutson. On average, PhaseBio Pharmaceuticals executives and independent directors trade stock every 52 days with the average trade being worth of $5,138. The most recent stock trade was executed by Clay Thorp on 19 May 2023, trading 3,750 units of PHAS stock currently worth $263.
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.
PhaseBio Pharmaceuticals executives and other stock owners filed with the SEC include: